More Clinical Articles

Clinical

The Innovation Blind Spot

Danielle Barron, (Feb 27, 2015)

Danielle Barron talks to author Ron Adner whose book “The Wide Lens” explains why the failure to focus on the entire ecosystem rather than the immediate environment of a new product is the downfall of pharmaceutical companies attempting to successfully commercialize innovation.
Access and Evidence

Real World Evidence: Maximize Benefits To Healthcare

Zuzanna Fimińska, (Feb 26, 2015)

With a staggering cost of drug development estimated at US$2.6 billion and a high failure rate of new compounds, pharma is under pressure to develop solutions that improve the R&D hit rate. Real World Evidence combined with digital healthcare might be what the industry is looking for.
Clinical

Engineering a Culture of Innovation Part 1: Creating a Win/Win Attitude

Dr Nicola Davies, (Feb 23, 2015)

“For the natural born innovator, risk and failure are akin to an old, comfortable pair of shoes” - Henry Doss, ecosystem architect and co-author of ‘The Rainforest Scorecard: A Practical Framework for Growing Innovation Potential.’ We investigate how a culture of innovation can be created.
Clinical

Fast and Frugal Experiments are the Way Forward

Dr Nicola Davies, (Feb 19, 2015)

We speak to co-author of The Innovator’s Method, Nathan Furr, about how pharma can enhance innovation, decrease costs, and accelerate drug discovery time frames with fast and frugal experiments in the face of uncertainty.
Clinical

Clinical Trials - Pharma in the Twittersphere

Dr Nicola Davies, (Feb 13, 2015)

The merging of the modern advent of the public Twittersphere with the traditional methodology of clinical trials has provided a patient-centric, patient-driven, and patient-funded opportunity within disease treatment research.
Clinical

Greater Transparency & Collaboration Critical to Drug Discovery

Zuzanna Fimińska, (Feb 11, 2015)

Scientific and organizational challenges are crippling pharma’s drug discovery efforts. Introducing new drugs depends on the industry’s ability to pool resources, cooperate, and embrace transparency.
Clinical

Leveraging Big Data to simplify clinical trials and fix R&D

Zuzanna Fimińska, (Feb 6, 2015)

Pharma needs to embrace Big Data and technology solutions that facilitate trials to cure R&D stagnation.
Clinical

Getting value from oral oncolytics

Adam Hill, (Feb 2, 2015)

Oral cancer drugs can offer a more convenient alternative to traditional IV therapies when it comes to treating patients, but issues such as adherence and reimbursement still need to be ironed out, while payers have to be convinced that oral agents represent value for money.
Clinical

Translating Patient Centricity into Organizational Reality

Adam Hill, (Jan 22, 2015)

Positive patient experiences and patient outcomes with high recruitment, adherence and retention result from alignment of the HEART, HEAD and HANDS within the research sponsor’s organization and among all key stakeholders.
Clinical

Open Data Sharing: Turf Wars v Innovation

Deirdre Coleman, (Jan 13, 2015)

There is consensus around the idea that greater access to patient-level clinical data is a good thing – good for science, business and humanity. However, sharing data brings with it a host of benefits, questions and risks for the industry.

Pages